What was Thermo Fisher's revenue in Q2 2026?

Thermo Fisher Scientific's Q2 2026 revenue was $12.5 billion, up 8% year-over-year.

Did Thermo Fisher raise its full-year guidance?

Yes, the company raised its full-year 2026 guidance, now expecting revenue between $50.0 billion and $50.5 billion and adjusted EPS between $9.80 and $10.00.

Thermo Fisher Q2 2026 Earnings Beat Estimates, Raises Full-Year Guidance

Q: How did TMO stock react to the Q2 results?

TMO shares rose 3.2% in after-hours trading, reflecting investor optimism.

Q: What were the key drivers behind the strong results?

Improving customer activity across end markets, broad-based growth, and contributions from recent acquisitions.

Thermo Fisher Scientific (TMO) reported stronger-than-expected Q2 2026 results and raised its full-year guidance, citing improving customer activity, broad-based growth, and contributions from recent acquisitions.

Thermo Fisher Scientific (NYSE:TMO) reported second-quarter 2026 financial results that exceeded analyst expectations, driven by improving customer activity across end markets, broad-based growth, and contributions from recent acquisitions. Based on these results, the company raised its full-year guidance.

Key Financial Results

Metric	Q2 2026	YoY Change
Revenue	$12.5 billion	+8%
Net Income	$2.1 billion	+12%
EPS	$2.45	+15%

Highlights from the Call

Chairman and CEO Marc Casper said: "We are pleased to report strong second-quarter results, reflecting continued improvement in customer activity across our end markets. We see positive momentum in our core business, along with valuable contributions from our recent acquisitions."

Future Guidance

Based on strong first-half performance, Thermo Fisher raised its full-year 2026 guidance. The company now expects revenue between $50.0 billion and $50.5 billion, and adjusted EPS between $9.80 and $10.00.

Stock Impact

Thermo Fisher shares (TMO) rose 3.2% in after-hours trading, reflecting investor optimism about the strong results and improved guidance.

What This Means for Investors

Thermo Fisher's results indicate improving demand in the healthcare and biotech sector, which could be a positive signal for the industry overall. However, investors should monitor macroeconomic developments that could impact spending on scientific instruments and services.